Late Ischemic Events After Clopidogrel Cessation Following Drug-Eluting Stenting. Should We Be Worried?**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.

Journal of the American College of Cardiology

Volumn 48, Issue 12, 2006, Pages 2592-2595

  Harrington, Robert A ^a   Califf, Robert M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PACLITAXEL; PYRIDINE DERIVATIVE; RAPAMYCIN;

CLINICAL RESEARCH; CLINICAL TRIAL; DRUG APPROVAL; DRUG ELUTING STENT; DRUG INDUSTRY; DRUG WITHDRAWAL; EDITORIAL; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; OBSERVATIONAL STUDY; PACKAGING; PRIORITY JOURNAL; SAMPLE SIZE; STENT; THROMBOSIS;

CORONARY STENOSIS; CORONARY THROMBOSIS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION INHIBITORS; STENTS; TICLOPIDINE;

EID: 33845294776     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.10.025     Document Type: Editorial

References (25)

1. American Heart Association. Heart and stroke facts. Available at: http://www.americanheart.org/presenter.jhtml?identifier=3000333. Accessed October 13, 2006.
2. Popma J.J., Berger P., Ohman E.M., et al. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 Suppl 3 (2004) 576S-599S
3. Al Suwaidi J., and Berger P.B. Do stents reduce mortality compared with balloon angioplasty?. A critical review of all the evidence. Am Heart J 150 (2005) 7-10
4. Tolleson T.R., Newby L.K., Harrington R.A., et al., SYMPHONY and the 2nd SYMPHONY Investigators. Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials). Am J Cardiol 92 (2003) 330-333
5. Leon M.B., Baim D.S., Popma J.J., et al., Stent Anticoagulation Restenosis study Investigators. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 339 (1998) 1665-1671
6. Berger P.B., Bell M.R., Hasdai D., et al. Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement. Circulation 99 (1999) 248-253
7. Moses J.W., Leon M.B., Popma J.J., et al., SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
8. Stone G.W., Ellis S.G., Cox D.A., et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350 (2004) 221-231
9. Smith Jr. S.C., Feldman T.E., Hirshfeld Jr. J.W., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention-summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 47 (2006) 216-235
10. Silber S., Albertsson P., Fernandez-Avilés F., et al. Guidelines for percutaneous coronary interventions. Eur Heart J 26 (2005) 804-847
11. Steinhubl S.R., Berger P.B., Mann III J.T., et al., CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002) 2411-2420
12. Yusuf S., Zhao F., Mehta S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
13. U.S. Food and Drug Administration. Available at: http://www.fda.gov/cdrh/safety/cypher.html. Accessed October 13, 2006.
14. Joner M., Finn A.V., Farb A., et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48 (2006) 193-202
15. Colombo A., and Corbett S.J. Drug-eluting stent thrombosis: increasingly recognized but too frequently overemphasized. J Am Coll Cardiol 48 (2006) 203-205
16. Pfisterer M., Brunner-La, Rocca H.P., Buser P.T., et al., BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
17. Kaiser C., Brunner-La Rocca H.P., Buser P.T., et al., BASKET Investigators. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 366 (2005) 921-929
18. Rao S.V., Shaw R.E., Brindis R.G., et al. American College of Cardiology National Cardiovascular Data Registry. On- versus off-label use of drug-eluting coronary stents in clinical practice (report from the American College of Cardiology National Cardiovascular Data Registry [NCDR]). Am J Cardiol 97 (2006) 1478-1481
19. Kandzari D.E., Roe M.T., Ohman E.M., et al. Frequency, predictors, and outcomes of drug-eluting stent utilization in patients with high-risk non-ST-segment elevation acute coronary syndromes. Am J Cardiol 96 (2005) 750-755
20. Updates from landmark DES trials: a mixed bag of questions and answers. Avialable at: http://www.theheart.org/article/740087.do. Accessed October 13, 2006.
21. Moses III H., Dorsey E.R., Matheson D.H., and Thier S.O. Financial anatomy of biomedical research. JAMA 294 (2005) 1333-1342
22. Moses III H., and Martin J.B. Academic relationships with industry: a new model for biomedical research. JAMA 285 (2001) 933-935
23. Spertus J.A., Kettelkamp R., Vance C., et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 113 (2006) 2803-2809
24. Barnes K. CROs set for world drug development domination. Available at: http://www.in-pharmatechnologist.com/news/ng.asp?id=70001. Accessed October 13, 2006.
25. Newby L.K., LaPointe N.M., Chen A.Y., et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 113 (2006) 203-212